Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
diabetic foot ulcers dfus epidemiology forecast insight

SALE

Diabetic Foot Ulcers (DFUs) - Epidemiology Forecast to 2034

Published Date : 2025

Pages : 100

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

diabetic foot ulcers dfus epidemiology forecast insight

DelveInsight’s ‘Diabetic Foot Ulcer (DFU) - Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted DFU epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2021-2034

Diabetic Foot Ulcer (DFU) Understanding

Diabetic Foot Ulcer Overview

Diabetic foot ulcer (DFU) is an open sore or wound in patients with diabetes; they occur in type 1 and type 2 diabetes mellitus. The average duration of diabetes before ulceration is >10 years. The wound is commonly located on the bottom of the foot. A DFU is caused by neuropathic (nerve) and vascular (blood vessel) complications of diabetes. Nerve damage due to diabetes causes altered or complete loss of feeling in the foot and/or leg, known as peripheral neuropathy.

DFU may result in an infection or other ulcer-related complications that can lead to hospitalization. Foot ulcers are a common complication of poorly controlled diabetes. Diabetic foot ulcers form when the lower layers are exposed after the skin tissues break down. When blood sugar levels are high or regularly fluctuate, skin that would usually heal may not properly repair itself because of nerve damage. These ulcers are most common under the big toes and the balls of feet and can affect the feet down to the bones.

DFUs are complex, chronic wounds, which have a major long-term impact on the morbidity, mortality, and quality of patients’ lives. Individuals who develop a DFU are at greater risk of premature death, myocardial infarction, and fatal stroke than those without a history of DFU. Unlike other chronic wounds, the development and progression of a DFU are often complicated by wide-ranging diabetic changes, such as neuropathy and vascular disease. In most DFU patients, peripheral neuropathy and peripheral arterial disease (PAD) (or both) play a central role. Therefore, DFU can be commonly classified into three types i.e. Neuropathic, Ischemic, and Neuro-ischemic.

Diabetic Foot Ulcer (DFU) Diagnosis

The most significant risk factors for foot ulceration are diabetic neuropathy, peripheral arterial disease, and consequent traumas of the foot. Other risk factors include tobacco use, alcohol consumption, poorly fitted or poor quality shoes, poor hygiene, improper trimming of toenails, poor glycemic control, and previous foot ulcerations. Diagnosis of DFU includes the doctor investigating the patient’s medical history for signs of any previous complication or medical condition. Other than this diagnosis of DFU requires a physical examination for checking the current condition, a few blood tests for screening any infection, and a metabolic profile to measure glucose levels. Radiological imaging tests, such as CT scan, MRI, Arteriography, etc. may also be used to gather detailed information about the DFU.

Epidemiology Perspective by DelveInsight

The DFU epidemiology division provides insights about historical and current DFU patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total prevalent case of DFU was 5,994,978 cases in the 7MM which are expected to grow during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted DFU epidemiology [segmented as Total Prevalent Cases of DFU, Total Diagnosed Cases of DFU, Gender-specific cases of DFU, Age-specific Cases of DFU, DFU cases by severity/chronicity of wound, and Treated cases of DFU] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- DFU Epidemiology

Estimates show that the highest cases of DFU in the 7MM were in the United States, followed by Italy, Germany, France, the United Kingdom, Spain, and Japan in 2020.

In the United States, the total number of prevalent cases of DFU was 4,551,498 cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.
In the year 2020, the total prevalent cases of DFU were 1,274,933 cases in EU-5 which are expected to grow during the study period, i.e., 2021-2034.
In Japan, the total number of prevalent cases of DFU was 168,547 cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.
In the 7MM, the total gender-specific prevalent cases of DFU were 2,149,948 for males and 1,374,864 for females in the year 2020.
In the 7MM, the total age-specific prevalent cases of DFU were 506,498, 1,529,831, and 1,488,484 cases for the age group less than 18–44, 45–64, and ≥75 years, respectively in 2020.

Scope of the Report

The DFU report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
The DFU Report and Model provide an overview of the risk factors and global trends of DFU in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
The report provides insight about the historical and forecasted patient pool of DFU in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of DFU.
The report provides the segmentation of the DFU epidemiology by total prevalent cases in the 7MM.
The report provides the segmentation of the DFU epidemiology by total diagnosed cases in the 7MM.
The report provides the segmentation of the DFU epidemiology by gender-specific prevalent cases in the 7MM.
The report provides the segmentation of the DFU epidemiology by age-specific prevalent cases in the 7MM.
The report provides the segmentation of the DFU epidemiology by severity/chronicity of wound in the 7MM.
The report provides the segmentation of the DFU epidemiology by treated cases in the 7MM.

Report Highlights

10-Year Forecast of DFU epidemiology
7MM Coverage
Total Prevalent Cases of DFU
Total Diagnosed Cases of DFU
Gender-Specific Prevalent Cases of DFU
Age-Specific Prevalent Cases of DFU
Severity/chronicity of wound Cases of DFU
Treated Cases of DFU

KOL-Views

We interview KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

What will be the growth opportunities in the 7MM concerning the patient population of DFU?
What are the key findings of the DFU epidemiology across the 7MM and which country will have the highest number of patients during the study period (2021-2034)?
What would be the total number of patients of DFU across the 7MM during the study period (2021-2034)?
Among the EU5 countries, which country will have the highest number of patients during the study period (2021-2034)?
At what CAGR the patient population is expected to grow in the 7MM during the study period (2021-2034)?
What are the various recent and upcoming events which are expected to improve the diagnosis of DFU?

Reasons to buy

The DFU Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global DFU market
Quantify patient populations in the global DFU market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the gender that presents the best opportunities for DFU therapeutics in each of the markets covered
Understand the magnitude of DFU population by its severity
The DFU epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
The DFU Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

Key Assessments

Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Diabetic Foot Ulcer (DFU)

3. SWOT Analysis of Diabetic Foot Ulcer (DFU)

4. Epidemiology Methodology

5. Diabetic Foot Ulcer (DFU): Disease Background and Overview

5.1. Introduction

5.1.1. Signs and Symptoms of DFU

5.1.2. Risk Factors and Causes of DFU

5.1.3. Pathophysiology of DFU

5.1.4. Classification of DFU

5.1.5. Complications of DFU

6. Diagnosis of Diabetic Foot Ulcer (DFU)

6.1. Medical History

6.2. Physical Examination

6.2.1. Assessment of possible vascular insufficiency

6.2.2. Assessment of possible peripheral neuropathy

6.2.3. Examination of ulcers and general circumstances of the extremities

6.3. Laboratory examination

6.3.1. Blood tests

6.3.2. Metabolic Profile

6.4. Radiological examination

6.4.1. Computed Tomographic (CT) scan and Magnetic Resonance Imaging (MRI)

6.4.2. Conventional Arteriography

6.4.3. Plain radiograms

6.4.4. Ultrasonography and Vascular examinations

6.5. Differential Diagnosis of DFU

7. Prevention of DFU

7.1. Daily Foot Inspection

7.2. Proper Footwear

7.3. Blood Sugar

7.4. Weight Loss

7.5. Tobacco Cessation

8. Diagnostic Guidelines of DFU

8.1. International Working Group on the Diabetic Foot (IWGDF) Guidelines

8.2. NICE Guidelines for Diabetic Foot Ulcers

9. Epidemiology and Patient Population

9.1. Epidemiology Key Findings

9.2. Assumptions and Rationale: 7MM

10. Epidemiology Scenario: 7MM

10.1. Total Prevalent Cases of DFU in the 7MM

10.2. Total Diagnosed cases of DFU in the 7MM

10.3. Gender-specific cases of DFU in the 7MM

10.4. Age-specific Diagnosed Cases of DFU in the 7MM

10.5. Severity/chronicity of wound-specific Diagnosed Cases of DFU in the 7MM

10.6. Treated cases of DFU in the 7MM

11. The United States Epidemiology

11.1. Total Prevalent Cases of DFU in the United States

11.2. Total Diagnosed cases of DFU in the United States

11.3. Gender-specific cases of DFU in the United States

11.4. Age-specific Diagnosed Cases of DFU in the United States

11.5. Severity/chronicity of wound-specific Diagnosed Cases of DFU in the United States

11.6. Treated cases of DFU in the United States

12. EU-5 Epidemiology

12.1. Germany

12.1.1. Total Prevalent Cases of DFU in Germany

12.1.2. Total Diagnosed cases of DFU in Germany

12.1.3. Gender-specific cases of DFU in Germany

12.1.4. Age-specific Diagnosed Cases of DFU in Germany

12.1.5. Severity/chronicity of wound-specific Diagnosed Cases of DFU in Germany

12.1.6. Treated cases of DFU in Germany

12.2. France

12.2.1. Total Prevalent Cases of DFU in France

12.2.2. Total Diagnosed cases of DFU in France

12.2.3. Gender-specific cases of DFU in France

12.2.4. Age-specific Diagnosed Cases of DFU in France

12.2.5. Severity/chronicity of wound-specific Diagnosed Cases of DFU in France

12.2.6. Treated cases of DFU in France

12.3. Italy

12.3.1. Total Prevalent Cases of DFU in Italy

12.3.2. Total Diagnosed cases of DFU in Italy

12.3.3. Gender-specific cases of DFU in Italy

12.3.4. Age-specific Diagnosed Cases of DFU in Italy

12.3.5. Severity/chronicity of wound-specific Diagnosed Cases of DFU in Italy

12.3.6. Treated cases of DFU in Italy

12.4. Spain

12.4.1. Total Prevalent Cases of DFU in Spain

12.4.2. Total Diagnosed cases of DFU in Spain

12.4.3. Gender-specific cases of DFU in Spain

12.4.4. Age-specific Diagnosed Cases of DFU in Spain

12.4.5. Severity/chronicity of wound-specific Diagnosed Cases of DFU in Spain

12.4.6. Treated cases of DFU in Spain

12.5. The United Kingdom

12.5.1. Total Prevalent Cases of DFU in the United Kingdom

12.5.2. Total Diagnosed cases of DFU in the United Kingdom

12.5.3. Gender-specific cases of DFU in the United Kingdom

12.5.4. Age-specific Diagnosed Cases of DFU in the United Kingdom

12.5.5. Severity/chronicity of wound-specific Diagnosed Cases of DFU in the United Kingdom

12.5.6. Treated cases of DFU in the United Kingdom

13. Japan Epidemiology

13.1. Total Prevalent Cases of DFU in Japan

13.2. Total Diagnosed cases of DFU in Japan

13.3. Gender-specific cases of DFU in Japan

13.4. Age-specific Diagnosed Cases of DFU in Japan

13.5. Severity/chronicity of wound-specific Diagnosed Cases of DFU in Japan

13.6. Treated cases of DFU in Japan

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Tables:

List of Table

Table 1: Summary of DFU, Epidemiology, and Key Events (2018–2030)

Table 2: Wagner Ulcer classification system

Table 3: The University of Texas Staging System for Diabetic Foot Ulcers

Table 4: Modified American Diabetes Association Diabetic Foot Risk Classification

Table 5: SINBAD Wound classification system

Table 6: PEDIS Wound classification system

Table 7: IWGDF Guideline on diagnosis, prognosis, and management of peripheral artery disease in patients with a foot ulcer and diabetes

Table 8: IWGDF Guideline on the diagnosis of foot infection in persons with diabetes

Table 9: List of Recommendations

Table 10: List of Recommendations

Table 11: Total Prevalent Cases of DFU in the 7MM (2018–2030)

Table 12: Total Diagnosed cases of DFU in the 7MM (2018–2030)

Table 13: Gender-specific cases of DFU in the 7MM (2018–2030)

Table 14: Age-specific Diagnosed Cases of DFU in the 7MM (2018–2030)

Table 15: Severity/chronicity of wound-specific Diagnosed Cases of DFU in the 7MM (2018–2030)

Table 16: Total Treated cases of DFU in the 7MM (2018–2030)

Table 17: Total Prevalent Cases of DFU in the United States (2018–2030)

Table 18: Total Diagnosed cases of DFU in the United States (2018–2030)

Table 19: Gender-specific cases of DFU in the United States (2018–2030)

Table 20: Age-specific Diagnosed Cases of DFU in the United States (2018–2030)

Table 21: Severity/chronicity of wound-specific Diagnosed Cases of DFU in the United States (2018–2030)

Table 22: Total Treated cases of DFU in the United States (2018–2030)

Table 23: Total Prevalent Cases of DFU in Germany (2018–2030)

Table 24: Total Diagnosed cases of DFU in Germany (2018–2030)

Table 25: Gender-specific cases of DFU in Germany (2018–2030)

Table 26: Age-specific Diagnosed Cases of DFU in Germany (2018–2030)

Table 27: Severity/chronicity of wound-specific Diagnosed Cases of DFU in Germany (2018–2030)

Table 28: Total Treated cases of DFU in Germany (2018–2030)

Table 29: Total Prevalent Cases of DFU in France (2018–2030)

Table 30: Total Diagnosed cases of DFU in France (2018–2030)

Table 31: Gender-specific cases of DFU in France (2018–2030)

Table 32: Age-specific Diagnosed Cases of DFU in France (2018–2030)

Table 33: Severity/chronicity of wound-specific Diagnosed Cases of DFU in France (2018–2030)

Table 34: Total Treated cases of DFU in France (2018–2030)

Table 35: Total Prevalent Cases of DFU in Italy (2018–2030)

Table 36: Total Diagnosed cases of DFU in Italy (2018–2030)

Table 37: Gender-specific cases of DFU in Italy (2018–2030)

Table 38: Age-specific Diagnosed Cases of DFU in Italy (2018–2030)

Table 39: Severity/chronicity of wound-specific Diagnosed Cases of DFU in Italy (2018–2030)

Table 40: Total Treated cases of DFU in Italy (2018–2030)

Table 41: Total Prevalent Cases of DFU in Spain (2018–2030)

Table 42: Total Diagnosed cases of DFU in Spain (2018–2030)

Table 43: Gender-specific cases of DFU in Spain (2018–2030)

Table 44: Age-specific Diagnosed Cases of DFU in Spain (2018–2030)

Table 45: Severity/chronicity of wound-specific Diagnosed Cases of DFU in Spain (2018–2030)

Table 46: Total Treated cases of DFU in Spain (2018–2030)

Table 47: Total Prevalent Cases of DFU in the United Kingdom (2018–2030)

Table 48: Total Diagnosed cases of DFU in the United Kingdom (2018–2030)

Table 49: Gender-specific cases of DFU in the United Kingdom (2018–2030)

Table 50: Age-specific Diagnosed Cases of DFU in the United Kingdom (2018–2030)

Table 51: Severity/chronicity of wound-specific Diagnosed Cases of DFU in the United Kingdom (2018–2030)

Table 52: Total Treated cases of DFU in the United Kingdom (2018–2030)

Table 53: Total Prevalent Cases of DFU in Japan (2018–2030)

Table 54: Total Diagnosed cases of DFU in Japan (2018–2030)

Table 55: Gender-specific cases of DFU in Japan (2018–2030)

Table 56: Age-specific Diagnosed Cases of DFU in Japan (2018–2030)

Table 57: Severity/chronicity of wound-specific Diagnosed Cases of DFU in Japan (2018–2030)

Table 58: Total Treated cases of DFU in Japan (2018–2030)

List of Figures:

List of Figures

Figure 1: Diabetic Foot Ulcer (DFU) SWOT Analysis

Figure 2: Epidemiology Methodology

Figure 3: Diabetic Foot Ulcer

Figure 4: Neuropathic DFU

Figure 5: Ischemic DFU

Figure 6: Neuro-ischemic DFU

Figure 7: Diabetic Foot Ulcer

Figure 8: Signs and symptoms of Diabetic Foot Ulcer

Figure 9: Causes of DFU

Figure 10: Risk factors of DFU

Figure 11: Mechanism of an ulcer developing in DFU from repetitive or excessive mechanical stress

Figure 12: Pathways to diabetic foot ulceration.

Figure 13: Complications of DFU

Figure 14: Ankle-Brachial Index Examination

Figure 15: Assessment of possible peripheral neuropathy using Garaptula and Monofilament

Figure 16: MRI Scan

Figure 17: Lower-Extremity Arteriography showing the anatomical variation of tibial arteries

Figure 18: Footwear for DFU patients

Figure 19: Total Prevalent Cases of DFU in the 7MM (2018–2030)

Figure 20: Total Diagnosed cases of DFU in the 7MM (2018–2030)

Figure 21: Gender-specific cases of DFU in the 7MM (2018–2030)

Figure 22: Age-specific Diagnosed Cases of DFU in the 7MM (2018–2030)

Figure 23: Severity/chronicity of wound-specific Diagnosed Cases of DFU in the 7MM (2018–2030)

Figure 24: Treated cases of DFU in the 7MM (2018–2030)

Figure 25: Total Prevalent Cases of DFU in the United States (2018–2030)

Figure 26: Total Diagnosed cases of DFU in the United States (2018–2030)

Figure 27: Gender-specific cases of DFU in the United States (2018–2030)

Figure 28: Age-specific Diagnosed Cases of DFU in the United States (2018–2030)

Figure 29: Severity/chronicity of wound-specific Diagnosed Cases of DFU in the United States (2018–2030)

Figure 30: Treated cases of DFU in the United States (2018–2030)

Figure 31: Total Prevalent Cases of DFU in Germany (2018–2030)

Figure 32: Total Diagnosed cases of DFU in Germany (2018–2030)

Figure 33: Gender-specific cases of DFU in Germany (2018–2030)

Figure 34: Age-specific Diagnosed Cases of DFU in Germany (2018–2030)

Figure 35: Severity/chronicity of wound-specific Diagnosed Cases of DFU in Germany (2018–2030)

Figure 36: Treated cases of DFU in Germany (2018–2030)

Figure 37: Total Prevalent Cases of DFU in France (2018–2030)

Figure 38: Total Diagnosed cases of DFU in France (2018–2030)

Figure 39: Gender-specific cases of DFU in France (2018–2030)

Figure 40: Age-specific Diagnosed Cases of DFU in France (2018–2030)

Figure 41: Severity/chronicity of wound-specific Diagnosed Cases of DFU in France (2018–2030)

Figure 42: Treated cases of DFU in France (2018–2030)

Figure 43: Total Prevalent Cases of DFU in Italy (2018–2030)

Figure 44: Total Diagnosed cases of DFU in Italy (2018–2030)

Figure 45: Gender-specific cases of DFU in Italy (2018–2030)

Figure 46: Age-specific Diagnosed Cases of DFU in Italy (2018–2030)

Figure 47: Severity/chronicity of wound-specific Diagnosed Cases of DFU in Italy (2018–2030)

Figure 48: Treated cases of DFU in Italy (2018–2030)

Figure 49: Total Prevalent Cases of DFU in Spain (2018–2030)

Figure 50: Total Diagnosed cases of DFU in Spain (2018–2030)

Figure 51: Gender-specific cases of DFU in Spain (2018–2030)

Figure 52: Age-specific Diagnosed Cases of DFU in Spain (2018–2030)

Figure 53: Severity/chronicity of wound-specific Diagnosed Cases of DFU in Spain (2018–2030)

Figure 54: Treated cases of DFU in Spain (2018–2030)

Figure 55: Total Prevalent Cases of DFU in the United Kingdom (2018–2030)

Figure 56: Total Diagnosed cases of DFU in the United Kingdom (2018–2030)

Figure 57: Gender-specific cases of DFU in the United Kingdom (2018–2030)

Figure 58: Age-specific Diagnosed Cases of DFU in the United Kingdom (2018–2030)

Figure 59: Severity/chronicity of wound-specific Diagnosed Cases of DFU in the United Kingdom (2018–2030)

Figure 60: Treated cases of DFU in the United Kingdom (2018–2030)

Figure 61: Total Prevalent Cases of DFU in Japan (2018–2030)

Figure 62: Total Diagnosed cases of DFU in Japan (2018–2030)

Figure 63: Gender-specific cases of DFU in Japan (2018–2030)

Figure 64: Age-specific Diagnosed Cases of DFU in Japan (2018–2030)

Figure 65: Severity/chronicity of wound-specific Diagnosed Cases of DFU in Japan (2018–2030)

Figure 66: Treated cases of DFU in Japan (2018–2030)

Tags:

License Type

Offer